Investors

Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We currently have 28 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.9 billion (IQVIA, February 2018).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."

Damian Finio
CFO

Recent News

Teligent, Inc. Announces First Quarter 2018 Results

BUENA, N.J. , May 08, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharm...

Learn More

Teligent, Inc. to Reschedule Conference Call for First Quarter 2018 Results

BUENA, N.J. , May 07, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharm...

Learn More

Teligent, Inc. to Present at Deutsche Bank’s 43rd Annual Health Care Conference on Tuesday May 8, 2018

BUENA, N.J. , May 01, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharma...

Learn More

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.


Investor Overview